Donghua Yin

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel‐Vinay, L Rhoda Molife et al. · The Lancet Oncology · 2009 · 338 citations · Full text

Anti-igf-1r Antibody Figitumumab, Medicine, Immunology +7

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Paul Haluska, Heather M. Shaw, Gretchen N. Batzel et al. · Clinical Cancer Research · 2007 · 266 citations

Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

Heribert Juergens, Najat C. Daw, Birgit Geoerger et al. · Journal of Clinical Oncology · 2011 · 209 citations · Full text

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Paul Haluska, F. Worden, David Olmos et al. · Cancer Chemotherapy and Pharmacology · 2009 · 190 citations · Full text

Refractory Adrenocortical Carcinoma, Medicine, Immunology +6

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Marcus Smith Noel, Eileen M. O’Reilly, Brian M. Wolpin et al. · Investigational New Drugs · 2019 · 174 citations · Full text